Tag: genomics
-
Liquid Biopsy Better Detects Lung Cancer Mutations
Tests of blood and urine from patients with a common form of lung cancer show these liquid biopsies more accurately identified cancer-causing mutations than traditional tissue sample biopsies.
-
Novartis Acquires Sickle-Cell Drug Developer
Drug maker Novartis is acquiring Selexys Pharmaceuticals Corp., a developer of treatments for pain episodes associated with sickle cell disease, for $665 million.
-
Large-Scale Cancer Gene Profiling Seen as Feasible
Genomic analysis of tumors, a growing practice for diagnosing cancer in individuals, is shown to be feasible when conducted routinely throughout a cancer care center.
-
Florida Voters Give Split Decision on GM Mosquitoes [Updated]
Voters in the Florida Keys yesterday returned a split decision on non-binding ballot questions about testing genetically modified mosquitoes to stop the Zika virus.
-
Synthetic Virus Created to Treat Cancer in Dogs
Two companies partnering with Auburn University developed a synthetic virus to find and destroy tumor cells in a type of bone cancer in dogs.
-
Gene Therapy Shown Helpful with Inherited Skin Disease
An early clinical trial shows genetically engineered skin grafts help heal some open wounds and appear safe for individuals with a serious inherited skin disorder.
-
Clinic Opens for Engineered T-Cell Cancer Therapies
A clinic to provide cancer treatments that use a patient’s immune system cells engineered to fight cancer is open at the Fred Hutchinson Cancer Research Center in Seattle.
-
Foundation Medicine, Sarah Cannon Partner on Cancer Trials
Foundation Medicine, a cancer diagnostics company, and Sarah Cannon Research Institute plan to apply genomic testing of patients’ tumors in clinical trials of personalized treatments.
-
Engineered Mosquito Production Facility Opens
A new industrial lab to produce mosquitoes genetically engineered to prevent the spread of infectious diseases opened in Piracicaba, Brazil.
-
Biotech, Novartis Partner on Rare Metabolic Diseases
A biotechnology start-up enterprise using genome editing for drug discovery is collaborating with drug maker Novartis on rare metabolic disorders.